As Fierce Pharma notes, sotrovimab had fairly spectacular results in Phase 2 and Phase 3 testing that showed 85% efficacy at preventing COVID-19 from becoming more severe. This level seemed unchanged against all variants, including against delta. And there’s a good reason to think that this antibody might keep being effective even should new variants knock vaccines or REGEN-COV for a loop.
){kind=link}